secwatch.observer — SEC 8-K summary
======================================

Issuer:     Poseida Therapeutics, Inc. (—)
CIK:        0001661460
Form:       8-K
Filed at:   2025-01-08T23:59:59+00:00
Accession:  0001193125-25-003248
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roche completes acquisition of Poseida Therapeutics for $9.00/share plus contingent value rights
--------------------------------------------------------------------------------

- Tender offer expired Jan 7, 2025; 66.11% of shares tendered, with an additional 8.01% via guaranteed delivery.
- Merger closed Jan 8, 2025; shareholders receive $9.00 per share cash plus CVRs up to $4.00 per share.
- Poseida becomes a wholly owned subsidiary of Roche Holdings; stock to be delisted from Nasdaq.
- Board and officers replaced by Roche appointees; Mark Gergen resigned as officer with severance.
- Loan agreement with Oxford Finance LLC terminated and fully repaid in connection with the merger.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661460/000119312525003248/0001193125-25-003248-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661460/000119312525003248/d874651d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-003248

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer